The reason is that camrelizumab can block the immunosuppressive state of T lymphocytes mediated by the PD-1 pathway, promote the activation of T lymphocytes, and rebuild the body’s immune function, thereby reducing the level of tumor markers. This evidence concerns the gene PDCD1 and neoplasm.